Novel Immunotherapy for Metastatic Bladder Cancer Using Vaccine of Human Interleukin-2 Surface-modified MB 49 Cells

作者：Zhang, Xinji; Shi, Xiaojun; Li, Jinlong; Hu, Zhiming; Guo, Fangfang; Huang, Xiao; Zhang, Zhehuan; Sun, Pengyu; Jing, Yuming; Gao, Jimin; Tan, Wanlong^*

来源：Urology, 2011, 78(3): 722.e1.

DOI：10.1016/j.urology.2011.04.044

OBJECTIVE To develop a novel protein-anchor technology to immobilize human interleukin-2 on tumor cells to induce antitumor immunity.
METHODS Interleukin-2 surface-modified MB49 cells were prepared as a vaccine. Subcutaneous and pulmonary metastatic mouse models of MB49 bladder cancer were used to evaluate the antitumor efficiency of the vaccine. Immunohistochemistry, flow cytometric, and cytotoxic T-lymphocyte assay were performed to assess the proportion and cytotoxicity of the T lymphocytes.
RESULTS The IL-2 surface-modified MB49 cell vaccine inhibited tumor growth and extended the survival of the mice, and the vaccine-cured mice effectively resisted the second MB49 but not the RM-1 prostate cancer cell challenge. Furthermore, more cytotoxicity on the MB49 cells and more CD4-positive, CD8-positive T cells appeared in the vaccine-treated group.
CONCLUSION The results of our study have demonstrated that the human interleukin-2 surface-modified MB49 bladder cancer cell vaccine induced specific antitumor immunity and was efficient against metastatic bladder cancer. UROLOGY 78: 722.e1-722.e6, 2011.

• 出版日期2011-9
• 单位温州医科大学; 南方医科大学